Conatus Pharma. Turns To Profit In Q2

(RTTNews) - Conatus Pharmaceuticals (CNAT) posted second-quarter net income applicable to common stockholders of $223,776, or $0.16 per share, compared to net loss of $1.8 million, or $1.81 per share in the comparable quarter last year.

On average, three analysts polled by Thomson Reuters expected the company to report a loss of $0.21 per share.

Research and development expenses were $1.1 million for each of the second quarter of 2013 and 2012, while general and administrative expenses were $0.7 million for the second quarter of 2013, compared to $0.6 million for the second quarter of 2012.